Compare TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock vs 10X Genomics Inc — how do they compare? TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $243.01 (market cap $46.84B), while 10X Genomics Inc trades at $57.99 (market cap $7.61B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 6.2× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals.
| TTWO | TXG | |
|---|---|---|
Market Cap | $46.84B | $7.61B |
Sector | Media | Health |
52-Week High | $262.29 | $58.57 |
52-Week Low | $189.69 | $11.34 |
Enterprise Value | $47.96B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Take-Two Interactive (TTWO) trades at $243.60, down 3.93% over 24 hours, with a bullish technical signal from moving averages and support near $240. The company reported Q1 2026 EPS of $0.80, beating estimates, but faces fundamental challenges with a net income margin of -4.79% and negative ROE of -9.04%. Recent news highlights strong GTA VI pre-orders as a key catalyst, with FY2027 net bookings guidance maintained at $8-$8.2 billion (company earnings report, August 7, 2026).
Outlook is optimistic due to GTA VI's November 2026 launch potential, but risks include high debt levels (debt-to-asset ratio of 39.87% in 2025) and consistent net losses. Analyst consensus is strongly bullish with a $300.55 price target, suggesting 23% upside from current levels if execution improves.
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
